Faes Farma’s recent strong run continued in Q2 16. While total revenue was up c.4% yoy to €57m in Q2 16, it increased 7% in H1 16 to €114m, primarily driven by Bilastine and well supported by mature products. Profitability remained strong with EBIT showing an increase of c.15% to €11.3m in Q2 16 (margin up 182bp to 19.8%), led by an improving product mix. Furthermore, the lower effective tax rate resulted in net profit growth of 21% to €10.6m (margin improved 259bp t
19 Aug 2016
Bilastine and Spain shrug off sluggishness in Portugal and Animal nutrition
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bilastine and Spain shrug off sluggishness in Portugal and Animal nutrition
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
19 Aug 2016 -
Author:
Jyoti Prakash -
Pages:
3
Faes Farma’s recent strong run continued in Q2 16. While total revenue was up c.4% yoy to €57m in Q2 16, it increased 7% in H1 16 to €114m, primarily driven by Bilastine and well supported by mature products. Profitability remained strong with EBIT showing an increase of c.15% to €11.3m in Q2 16 (margin up 182bp to 19.8%), led by an improving product mix. Furthermore, the lower effective tax rate resulted in net profit growth of 21% to €10.6m (margin improved 259bp t